Paysign (PAYS) Stock News

Paysign (NASDAQ: PAYS), a provider of patient affordability programs and donor compensation solutions, has appointed Jose Garcia as Executive Vice President of Life Science Solutions. Garcia, with over 20 years of executive experience, will lead the market strategy for the company's engagement and management solutions in life sciences.

Prior to joining Paysign, Garcia served as Vice President of Client Relationships at QualTex Laboratories, where he strengthened partnerships in blood and plasma collection industries. He previously held VP of Sales positions at BioBridge Global companies, QualTex and GenCure, expanding their life sciences presence.

Paysign (NASDAQ: PAYS) has announced the opening of a new 30,000 square foot patient service support center in Henderson, Nevada. The expansion increases the company's support capacity by 4x to meet growing demand in its patient affordability business.

The facility will enhance Paysign's ability to provide dedicated support specialists for individual programs and clients, leveraging its proprietary Dynamic Business Rules technology to optimize copay assistance programs. The company's patient affordability segment has shown remarkable growth, with revenues increasing 190% year-over-year in Q2 2025.

Paysign (NASDAQ: PAYS), a provider of payment solutions for life sciences industries, has announced its participation in the ninth annual Lake Street Best Ideas Growth BIG9 Conference on September 11, 2025. The invitation-only event facilitates interactions between small-cap companies and top institutional investors.

Chief Financial Officer Jeff Baker will represent Paysign at the conference, conducting one-on-one and group meetings with institutional investors throughout the event.

Paysign (NASDAQ: PAYS), a provider of patient affordability programs and payment solutions for life sciences industries, has appointed Dan Henry as Chairman of the Board. Henry succeeds Mark Newcomer, who will continue as President and CEO. Henry, who has served on Paysign's board since 2018, brings over 30 years of fintech leadership experience.

Henry's extensive background includes co-founding Euronet Worldwide, serving as CEO of NetSpend Corporation where he led its IPO and $1.4 billion acquisition by TSYS, and most recently serving as CEO of Green Dot Corporation. He currently chairs Paysign's Executive Compensation Committee and holds a B.S. in Business Administration from the University of Missouri.

Paysign (NASDAQ: PAYS), a provider of prepaid card programs and financial technology solutions, announced its participation in the upcoming Oppenheimer 28th Annual Technology, Internet & Communications Conference. The virtual conference will be held from August 11-13, 2025.

Chief Financial Officer Jeff Baker will represent the company with a presentation scheduled for Tuesday, August 12, at 10:45 a.m. EDT. The conference aims to showcase technological innovations and provide investors with insights into companies leading these advancements.

Paysign (NASDAQ: PAYS) reported strong Q2 2025 financial results with total revenues of $19.08 million, up 33.1% year-over-year. Net income reached $1.39 million, a 99.1% increase, with diluted EPS of $0.02. Adjusted EBITDA grew 101.8% to $4.51 million.

The company's pharma patient affordability segment showed exceptional growth with revenue increasing 189.9%, while adding 7 new programs for a total of 97 active programs. The plasma business added 123 new centers but saw a 4.7% revenue decline due to industry-wide plasma oversupply. The company exited Q2 with $11.8 million in unrestricted cash and zero debt.

Management raised full-year 2025 guidance, projecting revenues between $76.5-78.5 million, representing 32.7% growth at midpoint, with Adjusted EBITDA expected between $18.0-20.0 million.

Paysign (NASDAQ: PAYS), a fintech company specializing in prepaid card programs and payment solutions, has scheduled its second quarter 2025 earnings conference call for August 5, 2025, at 5:00 p.m. Eastern time.

The company will provide dial-in options for both U.S. (877.407.2988) and international (+1.201.389.0923) participants. A replay will be available through November 5, 2025, accessible via 877.660.6853 or +1.201.612.7415 with conference ID 13754588. Financial professionals interested in participating in the Q&A must register by emailing ir@paysign.com by August 1, 2025.

Paysign (NASDAQ: PAYS) has successfully transitioned 123 out of 132 newly awarded plasma donation centers in just one week, significantly ahead of schedule. The remaining 9 centers are expected to go live in Q3 2025. This rapid implementation showcases Paysign's operational capabilities, platform scalability, and efficient execution. The company, which provides patient affordability solutions and payment processing services, completed the transition without disrupting center operations or donor services. CEO Mark Newcomer highlighted that this expansion represents a crucial return to revenue growth for their plasma business unit, complementing the strong performance of their patient affordability segment. The achievement demonstrates Paysign's ability to deliver reliable, scalable, and compliant payment solutions to plasma collection organizations while reinforcing their position in the healthcare financial services sector.

Paysign (NASDAQ: PAYS) has secured a major expansion by being awarded 132 established plasma donation centers through an extended partnership with a major plasma collection company. The transition will occur in phases, with 123 centers expected to be operational by Q2 2025 and the remaining 9 centers in Q3 2025. This expansion increases Paysign's plasma center network to over 615 locations across 18 plasma collection companies, boosting their U.S. market share to approximately 50%. The new centers are projected to achieve 80% of Paysign's average revenue per center within weeks of onboarding and reach full revenue contribution by Q1 2026. Notably, the company expects no significant increase in SG&A expenses for these additional centers, demonstrating strong operational leverage.